Relay & Fio announce agreement with Unisys Corp. (NYSE:
TORONTO, Sep 17, 2021 (GLOBE NEWSWIRE) – Relay Medical Corp. (“Relay” or the “Company” (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) and Fio Corporation (“Fio”) – together through their joint venture, Fionet Rapid Response Group (“FRR”) – are pleased to announce an agreement with global IT solutions company, Unisys Corporation1 (NYSE: UIS)2, for the joint commercialization of a combined solution, which includes the FRR’s Fionet platform for pandemic and biosecurity management, for the large underserved biosecurity market.
FRR’s Fionet platform for pandemic and biosecurity management to be integrated into Unisys best-in-class U-Pass ™3, which digitally authenticates the health status of individuals. This combination of Fionet’s mobile testing, triage and reporting capabilities and U-Pass’s mobile authentication technologies will increase and simplify biosecurity management capability for customers in markets such as large enterprises, governments. , transport and maritime industries.
“Our goal is to create a safer environment for any public or private organization in any industry seeking to bring back employees, guests and students in large numbers quickly,” said Chris Kloes, Vice President, Cyber Security Solutions, Unisys Corp. “Together with FRR, we provide an integrated and secure digital health testing and management solution that can be scaled to organizations of any size, giving our customers greater control over who can access their environment. “
COVID-19 diagnostic products and services market expected to exceed US $ 84 billion4. FRR and Unisys believe they have a well-differentiated end-to-end offering by combining technology, marketing, and service and support capabilities.
“We are very excited to work with Unisys and continue to grow with other strategic relationships and industry leaders to collaborate and provide innovative market solutions. Our expertise in infectious disease screening and technology has been successful around the world for a variety of use cases, treating over one million patients, ”said Yoav Raiter, CEO of Relay Medical Corp. “Unisys has a strong presence in the IT solutions and business process market, which we are excited to begin integrating as we assess the many potential benefits of joining our technical strengths to achieve market penetration. ”
Unisys is a global leader in IT solutions bringing technological innovation to businesses and governments around the world. The company provides cutting-edge solutions, such as the comprehensive U-Pass ™ COVID-19 testing and health management solution, which was developed in response to the coronavirus pandemic. Unisys offers secure, reliable and advanced digital work, cloud and infrastructure, enterprise computing and enterprise processing solutions. Proudly incorporating security into all of its IT and digital offerings, Unisys provides a world-class software operating environment.
“This pandemic is not a transitional event, and life after COVID will not equal life before COVID. It’s a new era for all this interconnected world. In this new era, FRR is in a strong position to make a great contribution to the protection of people, jurisdictions and economic activity, and to develop its business by doing so. The FRR forges smart alliances with major companies such as Unisys, which have massive capacities to create long-lasting and large-scale solutions and customer relationships ”, said Dr Michael Greenberg, CEO of FRR.
FRR’s Fionet platform enables fast, scalable, quality-controlled testing and automatic, real-time digital results for electronic reporting. Fionet supports first-line testing and capture and continuously feeds comprehensive data to a centralized point of aggregation. In real time, Fionet portals allow offsite supervisors to track and direct frontline actions, displaying accurate epidemiological information and providing actionable insights.
The Company announces that it has granted a total of 500,000 options to purchase common shares of the Company at a price of $ 0.25 per common share and expiring five (5) years from the date of grant. , to certain officers, directors and consultants of the Company.
LATEST NEWS: Relay recently announced a $ 750,000 deployment of the Fionet Platform for Malaria Outbreak Management in Rwanda, Africa: https://bit.ly/2VKkTWQ
Additionally, the company recently announced other notable test deployments, including the Toronto Tennis Canada National Bank Open tournament, qualifying matches for FIFA 2021, and the Toronto International Film Festival with the largest lab company in the world. Canada.
SUBSCRIBE: For more information on Relay or to subscribe to the Company’s mailing list, visit: https://www.relaymedical.com/news
Unisys (NYSE: UIS) is a global IT solutions company delivering positive results to the most demanding businesses and governments. Unisys offerings include digital workplace solutions, cloud and infrastructure solutions, enterprise IT solutions, business process solutions and cybersecurity solutions. For more information on Unisys’ services for its customers in the commercial, financial and government markets.
The Fionet platform is a rapid end-to-end testing and monitoring solution for community or decentralized environments. Combining a fast portable point-of-need device connected in real-time to cloud data services, the Fionet platform manages scheduling and registration through a phone app for home, on-site and antigen testing. universal quick on site. The platform enables the integration of data with other testing methods and devices, providing notification of results to patients and public health authorities, where appropriate, and anonymized data and statistics for dashboards. authorized stakeholders.
Recent presentation and presentation video of the Fionet test platform:
About Relay Medical Corp.
Relay Medical is a technology innovator based in Toronto, Canada, focused on developing new solutions in the fields of diagnostics, AI data science and IoT security. Relay recently acquired Cybeats Technologies, a platform that offers a holistic approach to cybersecurity and addresses the $ 73 billion IoT security market through its software nomenclature and microagent solution. Cybeats provides real-time cybersecurity for connected devices, critical infrastructure, automotive, medical and IoT (Internet of Things) industries.
The company is holding a special meeting to approve a name change on September 20, 2021, as the company’s core competencies and product offerings have grown organically beyond the medical device industry, and this expansion in new industries and businesses will be reflected in the name change. The new name of the Company will more appropriately and effectively communicate the business and its verticals.
Caution regarding forward-looking information
Except for statements of historical fact, this press release contains certain “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “plan”, “intend”, “believe”, “anticipate”, “estimate” and other similar words. , or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on opinions and estimates at the date the statements are made and are subject to various risks and uncertainties and other factors that could cause actual events or results to differ materially from those. anticipated in forward-looking statements. statements, including, but not limited to, delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the control of the Company. There can be no assurance that the technology commercialization plans described in this press release will be effective on the terms or on the schedule described in this document. The Company assumes no obligation to update forward-looking information if circumstances or management’s estimates or opinions change, except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying the risks and uncertainties that could affect the financial results is contained in the documents filed by the Company with the Canadian securities regulators, which documents are available at www.sedar.com